mTOR treatment in lymphangioleiomyomatosis: the role of everolimus (Q38723770)

5 September 2017

1 reference

title

mTOR treatment in lymphangioleiomyomatosis: the role of everolimus (English)

1 reference

5 September 2017

Deborah H Yates

1

1 reference

5 September 2017

4 February 2016

1 reference

Expert Review of Respiratory Medicine

5 September 2017

1 reference

5 September 2017

10

1 reference

5 September 2017

249-260

1 reference

5 September 2017

3

1 reference

Lymphangioleiomyomatosis - a wolf in sheep's clothing.

5 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

The tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

PEComas: the past, the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Chylothorax in lymphangioleiomyomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Neurological and neuropsychiatric aspects of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Successful management of bilateral refractory chylothorax after double lung transplantation for lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

Radical reduction of smooth muscle cells in explanted lung of a LAM patient treated with sirolimus: first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1148603

10.1586/17476348.2016.1148603

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26847859